Notice of Correction to NOT-CA-18-071 "Notice of Intent to Publish a Funding Opportunity Announcement for the Fusion Oncoproteins in Childhood Cancers (FusOnC2) Consortium (U54)"

Notice Number: NOT-CA-18-086

Key Dates
Release Date:   June 26, 2018

Related Announcements
NOT-CA-18-071 

Issued by
National Cancer Institute (NCI)

Purpose

This Notice corrects the second paragraph under the subheading “Research Initiative Details” in the Purpose section of NOT-CA-18-071, Notice of Intent to Publish a Funding Opportunity Announcement for the Fusion Oncoproteins in Childhood Cancers (FusOnC2) Consortium (U54).

That paragraph currently reads:

“The FOA will focus on fusion oncoproteins found in tumors that have high risk of treatment failure and for which there has been little progress in identifying targeted agents. Responsive applications will be required to focus on one of the following fusion oncoproteins: EWSR1-FLI1 or related EWSR1 fusion oncoproteins (Ewing sarcoma); PAX-FOXO (alveolar rhabdomyosarcoma); SS18-SSX (synovial sarcoma); C11orf95–RELA (ependymoma); or NUP98 fusion proteins that occur in young children with AML. This list focuses on cancers for which there are no known effective targeted agents, and includes the most common fusion oncoproteins observed in pediatric solid tumors and brain tumors, as well as a high-risk leukemia that is refractory to current treatment strategies.”

That paragraph now reads:

“The FOA will focus on fusion oncoproteins found in tumors that have high risk of treatment failure and for which there has been little progress in identifying targeted agents. Responsive applications can focus on any fusion oncoprotein in pediatric solid tumors or on NUP98 fusion proteins that occur in young children with acute myelogenous leukemia (AML). However, greater preference will be given to applications focused on PAX-FOXO (alveolar rhabdomyosarcoma), C11orf95–RELA (ependymoma), or NUP98 fusion proteins.”

No other changes are being made to NOT-CA-18-071.

Inquiries

Please direct all inquiries to:

Keren Witkin, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-6250
Email: witkinkeren@mail.nih.gov